RxDoctor Payments Data

Gwen Nichols

Hematology & Oncology · New York, NYNPI 1801954326

Payments from drug & device makers

$926,678in general payments, 2019–2025

Across 5 payments — averaging $185,336 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$922K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Amgen$1K
  • Gilead$351
$4,746in research payments, 2019–2025

Across 4 payments — averaging $1186.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$5K

What the payments were for

  • Consulting fees$4,22592%
  • Food & beverage$3518%

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited1$922,102
E.r. Squibb & Sons, L.L.C.1$3,125
Amgen1$1,100
Gilead2$351

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$926,678 in reported general payments places this provider in the 85th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York

Other hematology & oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →